Study Evaluating the Addition of Pembrolizumab to Radium-223 in mCRPC

NCT03093428 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

45

Enrollment

OTHER

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: Radium-223
DRUG: Pembrolizumab

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]